

# Giada Sebastiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8452538/publications.pdf>

Version: 2024-02-01

120  
papers

6,387  
citations

71102

41  
h-index

69250

77  
g-index

121  
all docs

121  
docs citations

121  
times ranked

7510  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.   | 7.3 | 1,294     |
| 2  | Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.  | 1.3 | 575       |
| 3  | Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 686-693.   | 3.7 | 247       |
| 4  | Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. <i>World Journal of Gastroenterology</i> , 2006, 12, 3682.   | 3.3 | 220       |
| 5  | Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 52, 191-198.   | 3.7 | 188       |
| 6  | Chronic hepatitis C and liver fibrosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 11033.  | 3.3 | 178       |
| 7  | Liver fibrosis: Review of current imaging and MRI quantification techniques. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1276-1295.   | 3.4 | 163       |
| 8  | SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.   | 7.3 | 151       |
| 9  | Limitations of non-invasive tests for assessment of liver fibrosis. <i>JHEP Reports</i> , 2020, 2, 100067.   | 4.9 | 133       |
| 10 | Cloning and Characterization of the Murine Toll-like Receptor 5 (Tlr5) Gene: Sequence and mRNA Expression Studies in Salmonella-Susceptible MOLF/Ei Mice. <i>Genomics</i> , 2000, 64, 230-240.   | 2.9 | 125       |
| 11 | Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. <i>Journal of Hepatology</i> , 2010, 53, 630-638.  | 3.7 | 123       |
| 12 | Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2007, 13, 525.   | 3.3 | 123       |
| 13 | 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , 2020, 21, 617-624.  | 2.2 | 115       |
| 14 | Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.  | 3.7 | 113       |
| 15 | The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.                  | 3.7 | 111       |
| 16 | Pharmacological Targeting of the Hepcidin/Ferroportin Axis. <i>Frontiers in Pharmacology</i> , 2016, 7, 160.   | 3.5 | 100       |
| 17 | A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 1038-1044.  | 7.3 | 91        |
| 18 | Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5. | 4.4 | 90        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1937-1944.                             | 1.9 | 83        |
| 20 | Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , 2016, 30, 2635-2643.                              | 2.2 | 78        |
| 21 | Mapping of Genetic Modulators of Natural Resistance to Infection with <i>Salmonella typhimurium</i> Wild-Derived Mice. <i>Genomics</i> , 1998, 47, 180-186.   | 2.9 | 72        |
| 22 | Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. <i>European Radiology</i> , 2019, 29, 6477-6488.   | 4.5 | 72        |
| 23 | Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 801-808.                                 | 3.7 | 70        |
| 24 | Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. <i>World Journal of Gastroenterology</i> , 2009, 15, 2190.                      | 3.3 | 69        |
| 25 | Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. <i>World Journal of Gastroenterology</i> , 2016, 22, 7727.  | 3.3 | 65        |
| 26 | Systematic review: Preventive and therapeutic applications of metformin in liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 1652.   | 2.0 | 63        |
| 27 | Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw531.            | 5.8 | 60        |
| 28 | Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 124-133.                                 | 1.9 | 60        |
| 29 | Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , 2015, 10, e0128774.                         | 2.5 | 59        |
| 30 | An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.                               | 3.7 | 54        |
| 31 | Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2006, 13, 199-205.  | 2.0 | 51        |
| 32 | Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review. <i>International Journal of Drug Policy</i> , 2018, 57, 95-103. | 3.3 | 50        |
| 33 | Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0185192.           | 2.5 | 50        |
| 34 | Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , 2008, 15, 212-218.   | 2.0 | 49        |
| 35 | Conditional disruption of mouse HFE2 gene: Maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin. <i>Hepatology</i> , 2011, 54, 1800-1807.                                  | 7.3 | 49        |
| 36 | Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , 2006, 44, 83-87.                            | 3.7 | 48        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. <i>Metallomics</i> , 2011, 3, 971.  | 2.4 | 48        |
| 38 | How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 18-32.   | 2.0 | 46        |
| 39 | Natural history of initially mild chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2004, 36, 646-654.  | 0.9 | 45        |
| 40 | Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing. <i>Journal of Molecular Medicine</i> , 2013, 91, 95-102. | 3.9 | 44        |
| 41 | Physicians'™ Practices for Diagnosing Liver Fibrosis in Chronic Liver Diseases: A Nationwide, Canadian Survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 23-30.                        | 1.9 | 42        |
| 42 | Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study. <i>CMAJ Open</i> , 2020, 8, E429-E436.  | 2.4 | 42        |
| 43 | Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfectd with hepatitis D virus. <i>Journal of Viral Hepatitis</i> , 2012, 19, e170-6.                                       | 2.0 | 41        |
| 44 | Comparison of three algorithms of noninvasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104.   | 3.7 | 41        |
| 45 | HFE gene in primary and secondary hepatic iron overload. <i>World Journal of Gastroenterology</i> , 2007, 13, 4673.   | 3.3 | 38        |
| 46 | Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , 2018, 13, e0191985.  | 2.5 | 33        |
| 47 | Iron-Dependent Regulation of Hepcidin in HJV <sup>-/-</sup> Mice: Evidence That Hemojuvelin Is Dispensable for Sensing Body Iron Levels. <i>PLoS ONE</i> , 2014, 9, e85530.   | 2.5 | 32        |
| 48 | The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.   | 2.0 | 28        |
| 49 | Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e694-e701.                      | 5.8 | 27        |
| 50 | Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. <i>Liver Transplantation</i> , 2015, 21, 1383-1394.   | 2.4 | 26        |
| 51 | Incidence and Predictors of Hepatic Steatosis and Fibrosis by Serum Biomarkers in a Large Cohort of Human Immunodeficiency Virus Mono-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv015.   | 0.9 | 25        |
| 52 | Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020, 34, 237-244.  | 2.2 | 25        |
| 53 | Accelerated CCl <sub>4</sub> -Induced Liver Fibrosis in HJV <sup>-/-</sup> Mice, Associated with an Oxidative Burst and Precocious Profibrogenic Gene Expression. <i>PLoS ONE</i> , 2011, 6, e25138.                | 2.5 | 24        |
| 54 | Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. <i>Antiviral Research</i> , 2012, 96, 422-429.                            | 4.1 | 24        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 13-32.  | 2.3  | 23        |
| 56 | NASH in HIV. <i>Current HIV/AIDS Reports</i> , 2020, 17, 601-614.  | 3.1  | 23        |
| 57 | Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3017-3025.e6.  | 4.4  | 21        |
| 58 | AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.  | 0.9  | 20        |
| 59 | Clinical significance of elevated liver transaminases in HIV-infected patients. <i>Aids</i> , 2019, 33, 1267-1282.   | 2.2  | 19        |
| 60 | Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0262291.  | 2.5  | 19        |
| 61 | Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. <i>World Journal of Gastroenterology</i> , 2020, 26, 7046-7060.   | 3.3  | 18        |
| 62 | Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac003.  | 0.9  | 18        |
| 63 | Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.   | 3.7  | 18        |
| 64 | Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e188-e199.  | 12.3 | 18        |
| 65 | Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. <i>Journal of Viral Hepatitis</i> , 2020, 27, 205-220.                           | 2.0  | 17        |
| 66 | Intravoxel incoherent motion diffusion-weighted MRI for the characterization of inflammation in chronic liver disease. <i>European Radiology</i> , 2021, 31, 1347-1358.  | 4.5  | 17        |
| 67 | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , 2020, 71, 1831-1844.  | 7.3  | 16        |
| 68 | Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 942-950.  | 2.0  | 16        |
| 69 | Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. <i>Hepatology</i> , 2012, 56, 455-463.   | 7.3  | 15        |
| 70 | The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. <i>CMAJ Open</i> , 2019, 7, E674-E679.  | 2.4  | 14        |
| 71 | Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1422-1430.  | 5.8  | 14        |
| 72 | Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Mono-infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2184-e2193. | 5.8  | 14        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Occult cirrhosis diagnosed by transient elastography is a frequent and undermonitored clinical entity. <i>Liver International</i> , 2015, 35, 2285-2293.  | 3.9 | 13        |
| 74 | Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.   | 2.2 | 12        |
| 75 | Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 787-797.                          | 4.0 | 12        |
| 76 | Nonalcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and metaanalysis. <i>JGH Open</i> , 2021, 5, 434-445.   | 1.6 | 12        |
| 77 | Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis. <i>Hepatology</i> , 2018, 68, 783-785.  | 7.3 | 11        |
| 78 | Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817. | 5.8 | 11        |
| 79 | Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.  | 2.2 | 11        |
| 80 | Fatty liver in H63D homozygotes with hyperferritinemia. <i>World Journal of Gastroenterology</i> , 2006, 12, 1788.  | 3.3 | 9         |
| 81 | Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. <i>World Journal of Gastroenterology</i> , 2021, 27, 1959-1972.   | 3.3 | 7         |
| 82 | Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.  | 0.9 | 7         |
| 83 | Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 595-7.  | 2.3 | 6         |
| 84 | Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.                                    | 1.9 | 6         |
| 85 | MRI cine-tagging of cardiac-induced motion for noninvasive staging of liver fibrosis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1570-1580.   | 3.4 | 6         |
| 86 | Distinct Hepatitis B and HIV coinfected populations in Canada. <i>Journal of Viral Hepatitis</i> , 2021, 28, 517-527.   | 2.0 | 6         |
| 87 | Implementing non-invasive markers for liver fibrosis in clinical practice. <i>Journal of Hepatology</i> , 2008, 48, 880-881.  | 3.7 | 5         |
| 88 | Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107978.   | 2.3 | 5         |
| 89 | HIV, Elevated Transaminases, Fatty Liver: The Perfect Storm?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, e23-e25.   | 2.1 | 4         |
| 90 | Inference about time-dependent prognostic accuracy measures in the presence of competing risks. <i>BMC Medical Research Methodology</i> , 2020, 20, 219.  | 3.1 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.   | 3.9 | 4         |
| 92  | Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-positive patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1077-1082. | 3.7 | 3         |
| 93  | Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1385-1395.                | 1.6 | 3         |
| 94  | A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4046-4057.  | 2.3 | 3         |
| 95  | FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2396-2398.e3.   | 4.4 | 3         |
| 96  | Sarcopenic obesity at the crossroad of pathogenesis of cardiometabolic diseases. <i>Atherosclerosis</i> , 2021, 335, 84-86.   | 0.8 | 3         |
| 97  | “Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”, <i>HIV Medicine</i> , 2022, 23, 911-921.  | 2.2 | 3         |
| 98  | Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. <i>Lancet HIV</i> , 2022, 9, S4.   | 4.7 | 3         |
| 99  | Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. <i>World Journal of Hepatology</i> , 2021, 13, 2179-2191.   | 2.0 | 3         |
| 100 | Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , 2008, 15, 474-474.   | 2.0 | 2         |
| 101 | Letters to the Editor. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 219-220.  | 1.9 | 2         |
| 102 | Serpina3 is Overexpressed in the Liver in Presence of Iron Overload. <i>Journal of Investigative Medicine</i> , 2018, 66, 32-38.  | 1.6 | 2         |
| 103 | A190 REGRESSION OF LIVER FIBROSIS AFTER SUCCESSFUL ALL ORAL ANTIVIRAL THERAPY IN HCV CIRRHOSIS: A PILOT STUDY EMPLOYING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER (CAP). <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 331-331.                     | 0.3 | 2         |
| 104 | Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 994-1009.  | 2.4 | 2         |
| 105 | Letters to the Editor. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 221-222.  | 1.9 | 1         |
| 106 | Hepatic steatosis, hepatitis C, and human immunodeficiency viruses: A complex interplay. <i>Hepatology</i> , 2017, 66, 673-674.   | 7.3 | 1         |
| 107 | A199 SCREENING FOR NONALCOHOLIC FATTY LIVER DISEASE BY TRANSIENT ELASTOGRAPHY WITH CONTROLLED ATTENUATION PARAMETER IN UNSELECTED PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 347-348.                                    | 0.3 | 1         |
| 108 | Reply to “Transient Elastography in IBD Patients”, <i>Inflammatory Bowel Diseases</i> , 2019, 25, e95-e95.  | 1.9 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Nonalcoholic Fatty Liver Disease in Human Immunodeficiency Virus: The (Not So) New Kid on the Block?. Clinical Infectious Diseases, 2020, 71, 243-244.  | 5.8 | 1         |
| 110 | Optimizing patients with non-alcoholic fatty liver disease pre-transplant. Canadian Liver Journal, 2020, 3, 237-250.  | 0.9 | 1         |
| 111 | Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Research and Human Retroviruses, 2021, 37, 807-820.                    | 1.1 | 1         |
| 112 | The 8th Canadian Symposium on Hepatitis C virus: "Improving diagnosis and linkage to care". Canadian Liver Journal, 2020, 3, 3-14.  | 0.9 | 1         |
| 113 | Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. Journal of Personalized Medicine, 2022, 12, 282.   | 2.5 | 1         |
| 114 | Non-invasive algorithms for liver fibrosis: authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 35, 311-313.  | 3.7 | 0         |
| 115 | Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". Journal of Hepatology, 2018, 69, 1203-1204.   | 3.7 | 0         |
| 116 | Reply to Giannini et al. Clinical Infectious Diseases, 2021, 72, 1863-1864.   | 5.8 | 0         |
| 117 | Acute liver failure in ruptured sinus of Valsalva aneurysm. Canadian Liver Journal, 0, , e20210012.   | 0.9 | 0         |
| 118 | Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy?. , 2020, , 563-588.   |     | 0         |
| 119 | A110 FEASIBILITY OF EUS-GUIDED PORTAL PRESSURE GRADIENT MEASUREMENT WITHOUT DEEP SEDATION: A PATH TO ACCURATE PORTAL PRESSURE DETERMINATION. Journal of the Canadian Association of Gastroenterology, 2022, 5, 127-128.     | 0.3 | 0         |
| 120 | A220 THE IMPACT OF DIABETES AND AGE ON PERFORMANCE OF NON-INVASIVE SERUM-BASED TESTS FOR PREDICTION OF ADVANCED FIBROSIS IN BIOPSY-PROVEN NAFLD. Journal of the Canadian Association of Gastroenterology, 2022, 5, 109-110. | 0.3 | 0         |